Literature DB >> 22473764

A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis.

Daniele Campa1, Phillip Müller, Lutz Edler, Lena Knoefel, Roberto Barale, Claus P Heussel, Michael Thomas, Federico Canzian, Angela Risch.   

Abstract

ATP-binding cassette (ABC) transporter expression and genetic heterogeneity have been implicated in response to anticancer therapy. This study characterized genetic variability of the ABCB1 (also known as MDR1), ABCC2 (MRP2) and ABCG2 (BCRP) genes, which are key players in the metabolism of many chemotherapeutic agents including those used in the treatment of lung cancer. We genotyped 53 polymorphisms in the candidate genes in genomic DNA samples of 171 cases of small cell lung carcinoma (SCLC) and 206 cases of non-small cell lung carcinoma (NSCLC), and studied their impact on early response to chemotherapy, progression-free survival and overall survival. SNP rs717620 in ABCC2 was moderately associated with a poor response to chemotherapy but strongly with shorter progression-free survival and overall survival in SCLC but not NSCLC patients, indicating that ABCC2 genetic variation is an important factor in SCLC survival after chemotherapy.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22473764     DOI: 10.1002/ijc.27567

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

1.  Bitter melon extracts enhance the activity of chemotherapeutic agents through the modulation of multiple drug resistance.

Authors:  Deep Kwatra; Anand Venugopal; David Standing; Sivapriya Ponnurangam; Animesh Dhar; Ashim Mitra; Shrikant Anant
Journal:  J Pharm Sci       Date:  2013-10-15       Impact factor: 3.534

2.  The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.

Authors:  Yuan Yuan; Zhulin Yang; Xiongying Miao; Daiqiang Li; Ziru Liu; Qiong Zou
Journal:  Tumour Biol       Date:  2015-07-16

3.  Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer.

Authors:  Joel L Weissfeld; Brenda Diergaarde; Tomoko Nukui; Shama Buch; Arjun Pennathur; Mark A Socinski; Jill M Siegfried; Marjorie Romkes
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

4.  Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.

Authors:  Ning Ji; Yuqi Yang; Chao-Yun Cai; Zi-Ning Lei; Jing-Quan Wang; Pranav Gupta; Suneet Shukla; Suresh V Ambudkar; Dexin Kong; Zhe-Sheng Chen
Journal:  Cancer Lett       Date:  2018-10-10       Impact factor: 8.679

Review 5.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 6.  What do drug transporters really do?

Authors:  Sanjay K Nigam
Journal:  Nat Rev Drug Discov       Date:  2014-12-05       Impact factor: 84.694

7.  [Peripheral blood exosomes from patients with multiple myeloma mediate bortezomib resistance in cultured multiple myeloma cells].

Authors:  Juxian Tang; Qi Chen; Feng Zhang; Wenjun Zhang; Sirong Duan; Duan Xiao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-04-30

8.  The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients.

Authors:  Hannah Yejin Kim; Gareth J Veal; Fanfan Zhou; Alan V Boddy
Journal:  Eur J Clin Pharmacol       Date:  2018-08-30       Impact factor: 2.953

9.  Current Understanding of Membrane Transporters as Regulators or Targets for Cisplatin-Induced Hearing Loss.

Authors:  Kyle Z Pasquariello; Jason M Dey; Jason A Sprowl
Journal:  Mol Pharmacol       Date:  2021-07-30       Impact factor: 4.054

10.  The association of transporter genes polymorphisms and lung cancer chemotherapy response.

Authors:  Ying Wang; Ji-Ye Yin; Xiang-Ping Li; Juan Chen; Chen-Yue Qian; Yi Zheng; Yi-Lan Fu; Zi-Yu Chen; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.